Attaran, A. and Gillespie-White, L. (2001), ‘Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa?’, Journal of American Medical Association, 286(15):1886–1892.
Borrell, J.R. and Watal, J.(2002), ‘Impact of patents on access to HIV/AIDS drugs in developing countries’, Working paper 92, May 2002, Centre for International Development, Harvard University [Online]. Available: <www2.cid.harvard.edu/cidwp/092.pdf>.
Bloche, G.M. (2002), ‘WTO deference to national health policy: toward an interpretive principle’, Journal of International Economic Law, 5(4): 825–848.
Caves, R.E., Whinston, M.D.and Hurwitz, M.A.(1991), ‘Patent expiration, entry and competition in the US pharmaceutical industry’, Brookings Papers on Economic Activity: Microeconomics, 1–62.
Chaudhuri, S., Goldberg, P.K.and Jia, P.(2003), ‘The effects of extending intellectual property rights protection to developing countries: a case study of the Indian pharmaceutical market’, Working Paper 10159, National Bureau of Economic Research Working Paper Series, Cambridge [Online]. Available: www.nber.org/papers/W10159.
Cohen, J.C., Gyansa-Ludderodt, M.and Torpey, K.(2003), ‘Increasing access to medicines: policy options for Ghana: access to medicines advisory group consultative draft’, December 2003.
Commission on Human Rights, resolutions 2001/33, 2002/32 and 2003/29, Access to medication in the context of pandemics such as HIV/AIDS. E/CN.4/2002/2000; E/CN.4/RES/2001/33, E/CN.4/2003/L33.
Committee on Economic, Social, and Cultural Rights (2000), ‘The right to the highest attainable standard of health’, General Comment 14, UN Document E/C.12/2000/4.
Cook, A. (1998), ‘How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry’, Congressional Budget Office Study.
Correa, C.M. (2002), ‘Public health and intellectual property rights’, Global Social Policy, 2(3): 261–278.
Declaration ministérielle, adopted 14 November 2001. Doha, 2001. (WT/MIN(01)/DEC/1, 20 November 2001 (01-5859)) [Doha]
The Economist(2004), ‘South African pharmaceuticals: me too – welcome new investment in the generic drug industry’, 25 March 2004: 62.
Engdahl, E. (2005), ‘India alters patent views’, Legal Times, 11 July 2005.
Federal Register (2000), ‘Access to HIV/AIDS pharmaceuticals and medical technologies’, Executive Order 13155, Presedential Documents, Federal Register 65(93) 30521, 12 May 2000.
Forman, F. (2006), ‘Trading health for profit: bilateral and regional free trade agreements affecting domestic property rules on intellectual property rules on pharmaceuticals’, in Cohen, J.C.Schuklenk, U. and Illingsworth (eds), P.The Power of Pills: Social, Ethical, and Legal Issues in Drug Development, Marketing, and Pricing, London: Pluto Press.
Forman, L. (2007), ‘Trade rules, intellectual property and the right to health’, Ethics and International Affairs, 337(21): 3.
Gambardella, A., Orsenigo, L. and Pammoli, F.(2000), ‘Global competitiveness in pharmaceuticals, a European perspective’, Report prepared for the Directorate General Enterprise of the European Commission, November 2000.
Gervais, D. (1998), The TRIPS Agreement: Drafting History and Analysis, London: Sweet & Maxwell.
Goemaere, E., Kaninda, A.V.Ciaffi, L.Mulemba, M.Hoen, E.and Pecould, B. (2002), Letter to the Editor, Journal of American Medical Association, 287(7): 841.
Govindaraj, R., Reich, M.and Cohen, J.C.(2000), World Bank Pharmaceutical Discussion Paper, World Bank Publications.
Groombridge, M.A. (1999), ‘The TRIPS trade-off: reconciling competing interests in the millennium round’, Journal of World Intellectual Property, 2(6): 991–1013.
Helfer, L.R. (2004), ‘Regime shifting: the TRIPS Agreement and new dynamics of international intellectual property lawmaking’, Yale Journal of International Law, 29: 1.
Henry, D. and Lexchin, J.(2002), ‘The pharmaceutical industry as a medicines provider’, The Lancet, 360(9345): 1590–1595.
Hogerzeil, H.V., Samson, M.Casanovas, J.V.and Rahmani-Ocora, L.(2006), ‘Is access to essential medicines as part of the fulfilment of the right to health enforceable through the courts?’, The Lancet, 368(9532): 305–311.
Hollis, A. (2002), ‘The link between publicly funded health care and compulsory licensing’, Canadian Medical Association Journal, 167(7): 756–766.
International Federation of Pharmaceutical Manufacturers Association (2000), ‘TRIPS, pharmaceutical and developing countries: implications for health care access, drug quality and drug development’, International Federation of Pharmaceutical Manufacturer’s Association, Geneva.
Lazzarini, Z. (2003), ‘Making access to pharmaceuticals a reality: legal options under TRIPS and the case of Brazil’, Yale Human Rights Journal, 6:103–138.
Levison, L. and Laing, R.(2003), ‘The hidden costs of essential medicines’, WHO Essential Drugs Monitor, 33:20.
Loewenson, R. (2000), ‘Essential drugs in Southern Africa need protection from public health safeguards under TRIPS’, Bridges, Comment 3.
Love, J. (2007), ‘Recent examples of the movements on the use of compulsory licenses around the world’, in theMinistry of Public Health and the National Health Security Office Thailand, Facts and Evidences on the 10 Burning Issues Related to the Government Use of Patents on Three Patented Essential Drugs in Thailand, February 2007. Available : www.moph.go.th/hot/White%20Paper%20CL-EN.pdf
Mandavilli, A. (2007), ‘Reinventing an industry’, Nature, 445(7124): 138–139.
Mannan, A. and Story, A.(2006), ‘Abolishing the product patent: a step forward to global access to drugs’, in Cohen, J.C.Illingworth, P. and Schuklenk, U.The Power of Pills: Social, Ethical and Legal Issues in Drug Development, Marketing and Pricing, London: Pluto Press.
Maskus, K.E. (2000), Intellectual Property Rights in the Global Economy, Washington, DC: Institute for International Economics.
Maskus, K.E. (2006), Reforming US Policy: Getting the Incentives Right, CSR No. 19, Council on Foreign Relations, November 2006.
Maskus, K.E. and Lahouel, M.(1999), ‘Competition policy and intellectual property rights in developing countries: interests in unilateral initiatives and a WTO Agreement’, in the World Bank Global Conference on Developing Countries and the Millennium Round, Geneva, 20–21 September 1999, revision December 1999. Available: http://orion.forumone.com/ABCDE/files.fcgi/186_maskus.pdf.
Médecins Sans Frontières (2005), ‘Will the lifeline of affordable medicines for poor countries be cut? Consequences of Medicines Patenting in India’, Briefing document, February 2005.
Minister of Health and Another v. Treatment Action Campaign and Others (2002), 5 South African Law Report 721, Constitutional Court of South Africa.
Morgan, M.R. (2006), ‘Medicines for the developing world: promoting access and innovation in the post-TRIPS environment’, University of Toronto Faculty of Law Review, 64(1): 45.
Narrain, S. (2005), ‘Patents and public health concerns’, The Hindu, 15 November 2005.
Organisation for Economic Cooperation and Development, Directorate for Financial, Fiscal and Enterprise Affairs, Committee on Competition Law and Policy (2000), Competition and Regulation Issues in the Pharmaceutical Industry, DAFFE/CLP (2000)29, 6 February 2001.
Outterson, K. (2005), ‘Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets’, Yale Journal of Health Policy, Law and Ethics, 5: 193.
Penrose, E.T. (1951), The Economics of the International Patent System, Baltimore: Johns Hopkins Press, Chapter XI.
Prahalad, C.K. and Hammond, A.(2002), ‘Serving the world's poor, profitably’, Harvard Business Review, September 2002.
Reich, M. (2000), ‘The global drug gap’, Science, 287(5460): 1979–1981.
Roche Products Inc. v. Bolar Pharmaceutical Co. (1984), 733F.2d 838. Fed. Cir. of the US. 23 April 1984.
Rosenberg, T. (2001), ‘Look at Brazil’, New York Times Magazine, 20 February 2001.
Rozek, R.P. and Berkowitz, R.(1998), ‘The effects of patent protection on the prices of pharmaceutical products: is intellectual property protection raising the drug bill in developing countries?’, The Journal of World Intellectual Property, 1: 179–243.
Scherer, F.M. (2000), ‘The pharmaceutical industry’, in Culyer, A.L.and Newhouse, J.P. (eds), Handbook of Health Economics, Vol. 1, New York: Elsevier Science B.V.
Scherer, F.M. and Watal, J.(2001), ‘Post-TRIPS options for access to patented medicines in developing countries’, Commission on Macroeconomics and Health working paper WG4: 1, June 2001.
Singh, S. (2007), ‘Indian pharma enters the global arena’, Cell, 128(5): 811–814.
Thorsteinsdottir, H., Quach, U.Daar, A.S.and Singer, P.A.(2004), ‘Health biotechnology innovation in developing countries’, Nature Biotechnology, 22, Supplement December 2004.
Trebilcock, M.J. and Howse, R.(1999), The Regulation of International Trade, 2nd edn, New York: Routledge.
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) (1994), ‘Marrakesh agreement establishing the World Trade Organisation’, Annex 1C, 1869 U.N.T.S. 299, 33 I.L.M. 1197 (15 April).
Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R.and Ford, N.(2002), ‘Drug development for neglected diseases: a deficient market and a public-health policy failure’, The Lancet, 359(9324): 2188–2194.
UNAIDS and World Health Organisation (2006), ‘Progress on global access to HIV antiretroviral therapy’, Report on ‘3 by 5’ and beyond, March 2006, UNAIDS and WHO, Geneva.
United Nations Development Programme (2003), Making Global Trade Work for People, New York: United Nations Development Programme.
US Code Congressional and Administrative News (USCCAN) (1984), H.R.Rep. No. 98-857, Part I and 17 2647.
Weissman, R. (1996), ‘A long, strange TRIPS: the pharmaceutical industry drive to harmonise global intellectual property rules, and the remaining WTO legal alternatives available to third world countries’, University of Pennsylvania Journal of International Economic Law, 17(4): 1069–1125.
World Generic Markets (2005), ‘India passes patent amendments’, 30 March 2005.
World Health Assembly Resolution (2006), ‘Public health, innovation, essential health research and intellectual property rights: towards a global strategy and plan of action’, World Health Assembly 59.24, 27 May 2006.
World Health Organization (1998), ‘Progress of WHO member states in developing national drug policies and in revising essential drugs lists’, WHO/DAP/98.7, World Health Organization, Geneva.
World Health Organization (2002), ‘Implications of the Doha Declaration on the TRIPS Agreement and public health’, Health Economics and Drugs Series No.12, WHO/EDM/PAR/2002.3.
World Health Organization (2004), WHO Medicines Strategy: Countries at the Core 2004–2007, Geneva: World Health Organization.
World Health Organization and UNAIDS (1998), ‘Guidance modules on antiretroviral treatments: module 9: ethical and societal issues relating to antiretroviral treatments’, WHO/ASD/98.1, UNAIDS/98.7.
World Health Organization, UNAIDS, and UNICEF (2007) ‘Towards universal access: scaling up priority HIV/AIDS interventions in the health sector’, Progress report, World Health Organization, UNAIDS, and UNICEF, Geneva.
World Health Organization Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (2006), ‘Elements of a global strategy and plan of action’, A/PHI/IGWG/1/4, 2 November 2006.